Xencor, Inc Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31)
Xencor, Inc (XNCR) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) of $316.46 million as of 2017-12-31, per its 10-Q filed 2019-11-05.
Discontinued › Balance Sheet
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 · last filed 2019-11-05
- 2017-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) $316.46M.
- 2016-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) $337.93M; Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) as first filed $313.95M.
- 2015-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) $164.91M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) as first filed |
|---|---|---|
| 2017-12-31 | $316.46M 10-Q · filed 2019-11-05 | |
| 2016-12-31 | $337.93M 10-K · filed 2019-02-26 | $313.95M 10-Q · filed 2017-05-10 |
| 2015-12-31 | $164.91M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |